RxDoctor Payments Data

Elizabeth Ferluga, MD

Neurology · Nashville, TNNPI 1114121605

Payments from drug & device makers

$77,553in general payments, 2019–2025

Across 750 payments — averaging $103.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$44K
  • AbbVie$19K
  • MDD US Operations, LLC$6K
  • Teva Pharmaceuticals USA, Inc.$2K
  • Biohaven Pharmaceuticals, Inc.$1K
  • Acadia Pharmaceuticals Inc$679
  • plus $5K from 39 others

What the payments were for

  • Consulting fees$32,76543%
  • Speaking & faculty fees$24,44332%
  • Travel & lodging$7,0179%
  • Food & beverage$12,14316%
  • Education$5921%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$77,553 in reported general payments places this provider in the 80th percentile of 361 neurology providers in Tennessee.

See all neurology providers in Tennessee

Medicare billing

Part B allowed, 2024
$98,359
Medicare patients
91
Services billed
1,316

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate18$96,808
RytaryCarbidopa/Levodopa33$38,661
NeuproRotigotine24$21,490
Carbidopa-LevodopaCarbidopa/Levodopa122$4,080
Rasagiline Mesylate24$2,343
Carbidopa15$2,316
Rivastigmine14$1,689
Carbidopa-Levodopa ErCarbidopa/Levodopa37$1,179
Pramipexole DihydrochloridePramipexole Di-Hcl27$798
Donepezil Hcl35$526
Bupropion XlBupropion Hcl18$413
Gabapentin25$334
Sertraline Hcl41$302
Mirtazapine16$164
Ondansetron OdtOndansetron18$119

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$679$96,80818 claims
Amneal Pharmaceuticals LLCRytary$489$38,66133 claims
UCB, Inc.Neupro$155$21,49024 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 361 neurology providers in Tennessee.

Other neurology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →